{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:09:31Z","timestamp":1792634971582,"version":"4.5.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014942","name":"Novartis Gene Therapies Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014942","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ymthe.2025.02.025","type":"journal-article","created":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T18:57:31Z","timestamp":1739645851000},"page":"2842-2850","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Pilocytic astrocytoma in a child with spinal muscular atrophy treated with onasemnogene abeparvovec"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3533-533X","authenticated-orcid":false,"given":"Dorothea","family":"Holzwarth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Calaminus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Friese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Sejersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hildegard","family":"B\u00fcning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"John-Neek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella Luc\u00eda","family":"Bastone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Rothe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Mansfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana","family":"Libertini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Dubost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent","family":"Kuzmiski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iulian","family":"Alecu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Labik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janbernd","family":"Kirschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2025.02.025_bib1","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","article-title":"Observational study of spinal muscular atrophy type I and implications for clinical trials","volume":"83","author":"Finkel","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2025.02.025_bib2","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/ana.25101","article-title":"Natural history of infantile-onset spinal muscular atrophy","volume":"82","author":"Kolb","year":"2017","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymthe.2025.02.025_bib3","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13023-020-01356-1","article-title":"Longitudinal natural history of type 1 spinal muscular atrophy: a critical review","volume":"15","author":"Mercuri","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymthe.2025.02.025_bib4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/joa.12083","article-title":"Spinal muscular atrophy: a motor neuron disorder or a multi-organ disease?","volume":"224","author":"Shababi","year":"2014","journal-title":"J. Anat."},{"key":"10.1016\/j.ymthe.2025.02.025_bib5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/ejhg.2011.134","article-title":"Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72,400 specimens","volume":"20","author":"Sugarman","year":"2012","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.ymthe.2025.02.025_bib6","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.3390\/brainsci13101446","article-title":"Pharmacological therapies of spinal muscular atrophy: a narrative of preclinical, clinical-experimental, and real-world evidence","volume":"13","author":"Crisafulli","year":"2023","journal-title":"Brain Sci."},{"key":"10.1016\/j.ymthe.2025.02.025_bib7","series-title":"Zolgensma","year":"2025"},{"key":"10.1016\/j.ymthe.2025.02.025_bib8","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1093\/hmg\/ddq514","article-title":"Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice","volume":"20","author":"Domingues","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2025.02.025_bib9","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1146\/annurev.genet.37.110801.143717","article-title":"Integration of adeno-associated virus (AAV) and recombinant AAV vectors","volume":"38","author":"McCarty","year":"2004","journal-title":"Annu. Rev. Genet."},{"key":"10.1016\/j.ymthe.2025.02.025_bib10","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/mt.2016.52","article-title":"Recombinant AAV integration is not associated with hepatic genotoxicity in nonhuman primates and patients","volume":"24","author":"Gil-Farina","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.02.025_bib11","first-page":"17","article-title":"Promoter influences acute liver toxicity and long-term hepatic genotoxicity in rAAV SMA gene therapy mice","volume":"32","author":"Chen","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.02.025_bib12","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1172\/JCI79213","article-title":"Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy","volume":"125","author":"Chandler","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.02.025_bib13","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1126\/science.1142658","article-title":"AAV vector integration sites in mouse hepatocellular carcinoma","volume":"317","author":"Donsante","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.02.025_bib14","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1016\/j.ymthe.2021.08.031","article-title":"AAV integration in human hepatocytes","volume":"29","author":"Dalwadi","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.02.025_bib15","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1016\/j.ymthe.2022.06.004","article-title":"Evaluating the state of the science for adeno-associated virus integration: An integrated perspective","volume":"30","author":"Sabatino","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.02.025_bib16","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.omtm.2020.11.015","article-title":"Low incidence of hepatocellular carcinoma in mice and cats treated with systemic adeno-associated viral vectors","volume":"20","author":"Ferla","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.02.025_bib17","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1182\/blood.2023022589","article-title":"Vector integration and fate in the hemophilia dog liver multiple years after AAV-FVIII gene transfer","volume":"143","author":"Batty","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.02.025_bib18","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1182\/blood-2023-174468","article-title":"Childhood treatment with adeno-associated viral gene therapy results in stable FVIII Expression and improved bleeding phenotype in adult severe hemophilia A dogs","volume":"142","author":"Batty","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.02.025_bib19","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41587-020-0741-7","article-title":"A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells","volume":"39","author":"Nguyen","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.02.025_bib20","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ymthe.2005.03.020","article-title":"No evidence for tumorigenesis of AAV vectors in a large-scale study in mice","volume":"12","author":"Bell","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.02.025_bib21","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1016\/j.ymthe.2023.08.013","article-title":"Epithelioid neoplasm of the spinal cord in a child with spinal muscular atrophy treated with onasemnogene abeparvovec","volume":"31","author":"Retson","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.02.025_bib22","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1056\/NEJMoa1700554","article-title":"Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy","volume":"377","author":"Eichler","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.02.025_bib23","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa2113206","article-title":"Betibeglogene autotemcel gene therapy for non-\u03b20\/\u03b20 genotype \u03b2-thalassemia","volume":"386","author":"Locatelli","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.02.025_bib24","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1056\/NEJMoa2027675","article-title":"Autologous ex vivo lentiviral gene therapy for adenosine deaminase deficiency","volume":"384","author":"Kohn","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.02.025_bib25","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1089\/hum.2021.053","article-title":"Long-term follow-up of hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy","volume":"32","author":"Bougn\u00e8res","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.02.025_bib26","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.1182\/bloodadvances.2023009876","article-title":"Molecular evaluation and vector integration analysis of HCC complicating AAV gene therapy for hemophilia B","volume":"7","author":"Schmidt","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2025.02.025_bib27","first-page":"1","article-title":"Liver safety case report from the phase 3 HOPE-B gene therapy trial in adults with hemophilia B","volume":"5","author":"Schmidt","year":"2021","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"10.1016\/j.ymthe.2025.02.025_bib28","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s13244-014-0328-2","article-title":"Manifestations of pilocytic astrocytoma: a pictorial review","volume":"5","author":"Chourmouzi","year":"2014","journal-title":"Insights Imaging"},{"key":"10.1016\/j.ymthe.2025.02.025_bib29","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1126\/science.1088547","article-title":"LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1","volume":"302","author":"Hacein-Bey-Abina","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.02.025_bib30","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nm1393","article-title":"Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1","volume":"12","author":"Ott","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.02.025_bib31","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1172\/JCI31659","article-title":"Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy","volume":"117","author":"Deichmann","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.02.025_bib32","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1172\/JCI35700","article-title":"Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1","volume":"118","author":"Hacein-Bey-Abina","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.02.025_bib33","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1172\/JCI35798","article-title":"Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients","volume":"118","author":"Howe","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.02.025_bib34","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1056\/NEJMoa1003548","article-title":"Stem-cell gene therapy for the Wiskott\u2013Aldrich Syndrome","volume":"363","author":"Boztug","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.02.025_bib35","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nm.2088","article-title":"Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease","volume":"16","author":"Stein","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.02.025_bib36","doi-asserted-by":"crossref","first-page":"227ra33","DOI":"10.1126\/scitranslmed.3007280","article-title":"Gene therapy for Wiskott-Aldrich syndrome-long-term efficacy and genotoxicity","volume":"6","author":"Braun","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.02.025_bib37","unstructured":"U.S. Food and Drug Administration. (2021). Summary Basis for Regulatory Action. Slowing the progression of neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). https:\/\/www.fda.gov\/media\/162098\/download. Accessed 10 September 2024."},{"key":"10.1016\/j.ymthe.2025.02.025_bib38","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nature09328","article-title":"Transfusion independence and HMGA2 activation after gene therapy of human \u03b2-thalassaemia","volume":"467","author":"Cavazzana-Calvo","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.02.025_bib39","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","article-title":"Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells","volume":"558","author":"Fraietta","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.02.025_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2023.101159","article-title":"Analysis of vector genome integrations in multicentric lymphoma after AAV gene therapy in a severe hemophilia A dog","volume":"31","author":"Van Gorder","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.02.025_bib41","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood.2019004625","article-title":"BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression","volume":"137","author":"Konkle","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.02.025_bib42","series-title":"Exploratory analyses of healthy liver biopsies and a single case of parotid acinar cell carcinoma do not identify a role for Valoctocogene Roxaparvovec vector insertion in altering cell growth","author":"Eggan","year":"2022"},{"key":"10.1016\/j.ymthe.2025.02.025_bib43","unstructured":"Securities and Exchange Commission, Form 8-K. BioMarin Pharmaceuticals. 2022. https:\/\/app.quotemedia.com\/data\/downloadFiling?webmasterId=101533&ref=116942054&type=HTML&symbol=BMRN&companyName=BioMarin+Pharmaceutical+Inc.&formType=8-K&dateFiled=2022-09-12&CK=1048477. Accessed 6 January 2025."},{"key":"10.1016\/j.ymthe.2025.02.025_bib44","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/jvh.13915","article-title":"Integration and the risk of liver cancer-Is there a real risk?","volume":"31","author":"Kasimsetty","year":"2024","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.ymthe.2025.02.025_bib45","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa2109167","article-title":"Acute myeloid leukemia case after gene therapy for sickle cell disease","volume":"386","author":"Goyal","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.02.025_bib46","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/ajh.26741","article-title":"Lovo-cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB-206 study","volume":"98","author":"Kanter","year":"2023","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ymthe.2025.02.025_bib47","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1016\/j.ymthe.2022.11.001","article-title":"Vector genome loss and epigenetic modifications mediate decline in transgene expression of AAV5 vectors produced in mammalian and insect cells","volume":"30","author":"Handyside","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.02.025_bib48","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/hae.14936","article-title":"Long-term safety and efficacy outcomes of valoctocogene roxaparvovec gene transfer up to 6 years post-treatment","volume":"30","author":"Symington","year":"2024","journal-title":"Haemophilia"},{"key":"10.1016\/j.ymthe.2025.02.025_bib49","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.omtm.2023.04.009","article-title":"Comparing molecular and computational approaches for detecting viral integration of AAV gene therapy constructs","volume":"29","author":"Oziolor","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.02.025_bib50","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4103\/1658-631X.204857","article-title":"Spinal muscular atrophy and ependymoma","volume":"5","author":"Albakr","year":"2017","journal-title":"Saudi J. Med. Med. Sci."},{"key":"10.1016\/j.ymthe.2025.02.025_bib51","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.nmd.2004.09.013","article-title":"Alveolar rhabdomyosarcoma in infantile spinal muscular atrophy: coincidence or predisposition?","volume":"15","author":"Rudnik-Sch\u00f6neborn","year":"2005","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymthe.2025.02.025_bib52","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1177\/0883073814542950","article-title":"Neuroblastoma in a patient with spinal muscular atrophy type I: is it just a coincidence?","volume":"30","author":"Sag","year":"2015","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.ymthe.2025.02.025_bib53","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/00043426-200208000-00022","article-title":"Disseminated alveolar rhabdomyosarcoma in a child with spinal muscular atrophy","volume":"24","author":"Yaris","year":"2002","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.ymthe.2025.02.025_bib54","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro. Oncol."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625001157?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625001157?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T21:13:14Z","timestamp":1759612394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001625001157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":54,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1525001625001157"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.02.025","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pilocytic astrocytoma in a child with spinal muscular atrophy treated with onasemnogene abeparvovec","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.02.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}